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A B S T R A C T
Purpose: Valproic acid (VPA), which is widely used to treat epilepsy, migraine, and bipolar disorder, can
causes severe hyperammonemia. However, the mechanism responsible for this adverse effect is not
readily apparent. We previously reported that phenytoin coadministration is a strong risk factor for the
development of hyperammonemia during VPA-based therapy. In this study, we focused on glutamine
synthetase, which catalyzes the synthesis of glutamine from glutamate and ammonia and examined the
association with the development of hyperammonemia during VPA-based therapy.
Methods: For this study, we recruited 202 Japanese pediatric patients having epilepsy. We selected three
polymorphisms (rs10911070, rs10797771, and rs10911021) in the glutamine synthetase (GLUL) gene.
Hyperammonemia was deﬁned as a plasma ammonia level exceeding 200 or 170 mg/dL. We evaluated
the association between the development of hyperammonemia during VPA-based therapy and the
patient characteristics, including three GLUL polymorphisms.
Results: The number of patients who developed hyperammonemia during VPA-based therapy was 20
(9.9%) using the 200 mg/dL cutoff value and 30 (14.9%) using the 170 mg/dL cutoff value. Using a
multivariate logistic regression analysis, the GLUL rs10797771 polymorphism and phenytoin coadminis-
tration in the 200 mg/dL cutoff value, and female in addition to two factors in the 170 mg/dL cutoff value, had
signiﬁcant associations with a plasma ammonia level elevation during VPA-based therapy.
Conclusion: Phenytoin coadministration, GLUL rs10797771 polymorphism in the 200 mg/dL cutoff value,
and female in addition to two factors in the 170 mg/dL cutoff value, are independent risk factors for
elevated plasma ammonia levels during VPA-based therapy.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Valproic acid (VPA) is widely used to treat multiple conditions,
such as epilepsy, migraine, and bipolar disorder. However, it has
been reported that the incidence of abnormally elevated serum
ammonia level varies from 16.2% to 52.3% during VPA-based
therapy [1], and that the underlying mechanism responsible for
this increased plasma ammonia level is unclear. The factors known
to cause an increase in the plasma ammonia level include the VPA
daily dose [2], the duration of VPA treatment [3,4], and the* Corresponding author. Tel.: +81 54 264 5673; fax: +81 54 264 5674.
E-mail address: itohk@u-shizuoka-ken.ac.jp (K. Itoh).
http://dx.doi.org/10.1016/j.seizure.2015.10.015
1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights readditional use of antiepileptic drugs [5]. Previously, we reported
that VPA daily dose, gender, and phenytoin and/or phenobarbital
and/or topiramate coadministration are strongly linked with
exceeding 150 mg/dL as a plasma ammonia level during VPA-
based therapy, based upon a large-scale examination intended for
Japanese pediatric patients having epilepsy [6].
A link has been suggested between a genetic polymorphism
(4217C>A) in the gene encoding mitochondrial carbamoyl-
phosphate synthase 1 (CPS1) and severe hypreammonemia
(plasma ammonia level 3 200 mg/dL) during VPA-based therapy
in pediatric patients having epilepsy [7]. The CPS1 enzyme, a
component of the urea cycle, transfers ammonia from the amide
group of glutamine to a molecule of bicarbonate, consuming ATP
and producing carbamoyl-phosphate in the process [8]. However,served.
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polymorphism was strongly related to exceeding the plasma
ammonia level of 200 mg/dL during VPA-based therapy in our
previous examination of 177 Japanese pediatric patients having
epilepsy [9].
Ammonia is also consumed by glutamine synthetase, in
addition to the urea cycle. The enzymatic activity of glutamine
synthetase, which is widely expressed in the liver, brain,
gastrointestinal tract, and peripheral lymphocyte [10], decreases
on phenytoin administration [11]. Polymorphisms have also been
identiﬁed in the glutamine synthetase gene (GLUL). We selected
three single nucleotide polymorphisms (rs10911021, rs10911070,
and rs10797771) in GLUL gene. Because the rs10911021 polymor-
phism, which is located at 30 untranslated region of the GLUL gene,
has been associated with the enzymatic activity of glutamine
synthetase [12]. In this study, the GLUL rs10911021 polymorphism
was associated with an elevated the risk of coronary heart disease
in type 2 diabetes. As compared to T allele homozygotes in the
GLUL rs10911021 polymorphism, the expression of the GLUL gene
in a C allele homozygote was decreased by 32% in human
endothelial cells. Arai et al. examined the association between 6
GLUL polymorphisms and schizophrenia susceptibility and
reported no signiﬁcant differences [13]. From these 6 GLUL
polymorphisms, we selected the rs10911070 and rs10797771
polymorphisms located in the upstream region, which may also
affect the enzymatic activity of glutamine synthetase.
This study was designed to examine the inﬂuence of patient
characteristics (age, gender, body weight, VPA concentration, VPA
daily doses, adjusted VPA concentration, number of antiepileptic
drugs, and concomitant antiepileptic drug use) and GLUL
polymorphisms (rs10911070, rs10797771, and rs10911021) on
the development of hyperammonemia in 202 Japanese pediatric
patients having epilepsy. Hyperammonemia was deﬁned using
two different cutoff values in this study: a plasma ammonia levels
exceeding 200 mg/dL and 170 mg/dL. These levels were chosen
because plasma ammonia concentrations exceeding 200 mg/dL are
known to cause severe coma and respiratory failure leading to life-
threatening conditions [14], and concentrations greater than
170 mg/dL (100 mmol/L) are associated with neurological symp-
toms [15].
2. Materials and methods
2.1. Patients
This study was conducted in accordance with the Declaration of
Helsinki and Good Clinical Practice guidelines and was approved
by the Ethics Committee of the Shizuoka Institute of Epilepsy and
Neurological Disorders and the University of Shizuoka, Shizuoka,
Japan. From January 2006 to December 2013, we enrolled
202 Japanese patients having pediatric epilepsy (age, 0–15 years)Table 1
Three gltamate synthetase (GLUL) genetic polymorphisms and primers of PCRs, and co
GLUL polymorphisms Polymorphism
localization
Primers 
rs10911070 G>A Upstream region F: 50-ACGTGGAAAGTTGG
R: 50-GCATACCCAGGATTG
rs10797771 C>T Upstream region F: 50-GCAGGGGTTAGCTT
R: 50-AAACTTGGGCCCTG
rs10911021 C>T 30 untranslated region F: 50-GCCAGGCACTTTTAA
R: 50-CAATGACGAGATGG
F, forward primer; R, reverse primer.who were being treated with VPA and undergoing blood ammonia
measurements. This is a retrospective study and the study
population included both inpatients and outpatients at the
Shizuoka Institute of Epilepsy and Neurological Disorders. A
portion of the subjects participated in our previous study [9], and
the others were newly recruited subjects. Written informed
consent was obtained from each subject or their guardian after
a detailed brieﬁng of the study purposes and protocols. We
obtained blood samples for the analysis of GLUL polymorphisms
from each patient and retrospectively reviewed electronic medical
records for patient characteristics, age, gender, body weight,
plasma ammonia level, liver function, concomitant antiepileptic
drugs, VPA daily dose, and VPA concentration. Potential subjects
who showed noncompliance with therapy, those with severe
hepatic or renal dysfunction (aspartate aminotransferase or
alanine aminotransferase > 500 U/L and/or serum creatini-
ne > 3.0 mg/dL), those on a ketogenic diet, and those with
intercurrent infection were excluded.
2.2. Measurement of plasma ammonia levels and VPA concentration
Blood samples were drawn from each subject into a heparinized
tube, which was placed on ice as soon as possible after collection.
The plasma ammonia level was promptly measured using a
bromophenol blue colorimetric test conducted with a VITROS5600
autoanalyzer system (Ortho Clinical Diagnostics, Tokyo, Japan). A
separate blood sample obtained at the same time was used for
measuring the VPA concentration. This sample was centrifuged at
3000 rpm, after which the VPA concentration was measured with a
latex immunoagglutination assay using the same autoanalyzer.
With respect to blood ammonia level, we selected the highest
value in each patient during VPA treatment.
2.3. Genotyping procedures
Peripheral blood was drawn from subjects using ethylenedia-
minetetraacetic acid (EDTA)-2Na Venoject II tubes (Terumo, Tokyo,
Japan). Genomic DNA was isolated from these blood samples by
using a MagNA Pure Compact System (Roche Diagnostics,
Mannheim, Germany). The genotypes of three GLUL polymor-
phisms (rs10911021, rs10911070, and rs10797771) were deter-
mined using a newly established polymerase chain reaction-
restriction fragment length polymorphism – (PCR-RFLP) based
method. The scheme is shown in Table 1. In brief, genomic DNA
(100 ng) was ampliﬁed in the PCR buffer containing dNTP mixture
(200 mM), forward primer (1 mM), and reverse primer (1 mM),
HotStar Taq plus DNA polymerase (1.25 units; Qiagen, Tokyo,
Japan), and MgCl2 (1.5 mM). Ampliﬁcation was performed using an
i-Cycler thermal cycler (Bio-Rad, Tokyo, Japan). PCR comprised an
initial denaturation/enzyme activation step at 95 8C for 5 min,
ampliﬁcation for 35 cycles at 94 8C for 30 s, an appropriaterresponding resriction enzymes.
Annealing
temperature (8C)
Restriction
enzymes
Digest
fragments (bp)
GAAGAA-30 56 AvaII G: 362
A: 96 + 266
AGAGG-30
GAGAGG-30 60 BglI C: 82 + 223
T: 305
AAAGAC-30
AGAGCT-30 60 NlaIII C: 56 + 60
T: 116
GAACACG-30
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ﬁnal extension step at 72 8C for 10 min. PCR products were
digested with each restriction enzyme (New England BioLab,
Beverly, MA, USA) according to the manufacturer’s instructions
(Table 1). Digested products were separated by electrophoresis on
a 4% agarose gel, and the genotype was assigned based on the
results of the analysis of the digestion patterns. The accuracy of this
PCR-RFLP-based method was conﬁrmed by direct sequencing of
the ampliﬁed PCR product.
2.4. Statistical analysis
Derivation of the genotyping data from the Hardy–Weinberg
equilibrium was assessed using the chi-square test for goodness-of
ﬁt. A 2-tailed chi square test or 2-tailed Fisher’s exact test was used
to compare quantitative variables (age, gender, body weight, VPA
concentration, VPA daily doses, adjusted VPA concentration, the
number of antiepileptic drugs, concomitant antiepileptic drugs,
and three GLUL polymorphisms) between patients with or without
the development of hyperammonemia in a univariate analysis. For
age, body weight, VPA concentration, VPA daily doses, adjusted
VPA concentration, and the number of antiepileptic drugs used,Table 2
Patient characteristics and results of univariate analyses for the factors that predict th
Number of patients (% of total) or
mean  standard deviation (S.D.)
p 
Hyperammonemia
(3200 mg/dL)
Non-hyperammonemia
(<200 mg/dL)
n = 20 n = 182 
Age (years) 8.20  4.66 5.82  4.21 0.0
Gender (male/female) 8 (40.0)/12 (60.0) 94 (51.6)/88 (48.4) 0.3
Body weight (kg) 22.10  11.33 21.78  13.18 0.1
Valproic acid concentration
(mg/mL)
76.46  22.49 77.99  31.59 0.3
Valproic acid daily
doses (mg/kg)
24.92  9.14 22.36  9.40 0.9
Adjusted valproic acid
concentration
((mg/mL)/(mg/kg))
3.27  1.16 3.74  1.47 0.3
Number of anti-epileptic
drugs
2.55  0.69 2.66  0.95 0.8
Concomitant drugs with valproic acid
Clobazam 3 (15.0) 53 (29.1) 0.1
Phenytoin 11 (55.0) 33 (18.1) <0
Zonisamide 4 (20.0) 38 (20.9) 1.0
Topiramate 2 (10.0) 32 (17.6) 0.5
Carbamazepine 3 (15.0) 23 (12.6) 0.7
Phenobarbital 3 (15.0) 25 (13.7) 0.7
Lamotrigine 1 (5.0) 18 (9.9) 0.7
Ethosuximide 1 (5.0) 14 (7.7) 0.3
Clonazepam 0 (0) 13 (7.1) 0.3
Bromide 0 (0) 13 (7.1) 0.3
Stiripentol 0 (0) 10 (5.5) 0.6
Levetiracetam 0 (0) 8 (4.4) 1.0
Sultiame 0 (0) 1 (3.8) 1.0
Acetazolamide 1 (5.0) 6 (3.3) 0.5
Gabapentin 0 (0) 6 (3.3) 1.0
Nitrazepam 1 (5.0) 2 (1.1) 0.2
Primidone 0 (0) 1 (0.6) 1.0
GLUL rs10911070 G>A GG: 6, AG: 13, AA: 1
(G: 0.625, A: 0.375)11
GG: 63, AG: 95, AA: 24
(G: 0.607, A: 0.393)11
0.4
0.6
GLUL rs10797771 C>T CC: 1, CT: 12, TT: 7
(C: 0.350, T: 0.650)11
CC: 10, CT: 67, TT: 105
(C: 0.239, T: 0.761)11
0.1
0.0
GLUL rs10911021 C>T CC: 7, CT: 12, TT: 1
(C: 0.650, T: 0.350)11
CC: 93, CT: 79, TT: 10
(C: 0.728, T: 0.272)11
0.3
0.1
1 2-tailed chi-square test, 2<6 vs. 36, 3218 vs. >18, 4<77 vs. 377, 5<22 vs. 322, 623.3
10 comparison between 2 groups, AA+AG vs. GG in rs10911070, CC+CT vs. TT in rs1079
included in the multivariate logistic regression analysis.2 groups were established based on the median value of each
endpoint. The variables that showed a moderate relationship
(p < 0.15) with the development of hyperammonemia in a
univariate analysis were included in the multivariate logistic
regression analysis. The ﬁnal model was built using the stepwise
method (p < 0.05). All statistical analyses were performed using
SPSS ver.18.0 software (IBM, Tokyo, Japan). Statistical differences
at p < 0.05 were considered to be signiﬁcant.
3. Results
3.1. Patient characteristics and VPA therapy
Patient characteristics are presented in Table 2. The number of
patients that developed hyperammonemia during VPA-based
therapy was 20 (9.9%) using the 200 mg/dL cutoff value and 30
(14.9%) using the 170 mg/dL cutoff value. The distributions of the
three GLUL polymorphisms were not signiﬁcantly different from
those predicted using the Hardy–Weinberg equilibrium. Substan-
tial fractions of the patients received dual (77, 38.1%) or triple (74,
37.1%) antiepileptic drug therapies, including VPA. The drug moste development of hyperammonemia during valproic acid-based therapy.
Number of patients (% of total) or mean  standard
deviation (S.D.)
p
Hyperammonemia
(3170 mg/dL)
Non-hyperammonemia
(<170 mg/dL)
n = 30 n = 172
731, 2, 12 7.80  4.67 5.91  4.13 0.0631, 2, 12
231 10 (33.3)/20 (66.6) 92 (53.5)/80 (46.5) 0.0421, 12
721, 3 23.65  13.25 21.49  12.95 0.1271, 3, 12
231, 4 77.36  24.86 77.92  31.74 0.3951, 4
631, 5 24.38  9.34 22.31  9.38 0.4641, 5
231, 6 3.53  1.60 3.72  1.42 0.2131, 6
851, 7 2.80  0.76 2.63  0.95 0.1161, 7, 12
811 6 (20.0) 50 (29.1) 0.3061
.0011, 12 16 (53.3) 28 (16.3) <0.0011, 12
008 5 (16.7) 37 (21.5) 0.5461
388 6 (20.0) 28 (16.3) 0.6151
278 5 (16.7) 21 (12.2) 0.5548
458 3 (10.0) 25 (14.5) 0.7748
008 2 (6.7) 17 (9.9) 0.7458
718 1 (3.3) 14 (8.1) 0.7048
718 2 (6.70) 11 (6.4) 1.0008
718 1 (3.3) 12 (7.0) 0.6968
038 1 (3.3) 9 (5.2) 1.0008
008 0 (0) 8 (4.7) 0.6088
008 0 (0) 7 (4.1) 0.5978
248 3 (10.0) 4 (2.3) 0.0698, 12
008 0 (0) 6 (3.5) 0.5958
708 2 (3.3) 1 (0.6) 0.0588, 12
008 0 (0) 1 (0.6) 1.0008
401, 9 GG: 10, AG: 18, AA: 2
(G: 0.633, A: 0.367)11
GG: 59, AG: 90, AA: 23
(G: 0.605, A: 0.395)11
0.5441, 9
801, 10 0.9181, 10
251, 9 CC: 2, CT: 17, TT: 11
(C: 0.350, T: 0.650)11
CC: 9, CT: 62, TT: 101
(C: 0.233, T: 0.767)11
0.0781, 9
531, 10, 12 0.0251, 10, 12
581, 9 CC: 14, CT: 15, TT: 1
(C: 0.717, T: 0.283)11
CC: 86, CT: 76, TT: 10
(C: 0.721, T: 0.279)11
0.7641, 9
721, 10 0.7361, 10
8 vs. >3.38, 7<3 vs. 33, 8 2-tailed Fisher’s exact test, 9 comparison among 3 groups,
7771, CC vs. CT+TT in rs10911021, respectively. 11 Allele frequencies, 12 p < 0.15,
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and zonisamide.
3.2. Association between patient variables and the development of
hyperammonemia
We evaluated each potential risk factor for the development of
hyperammonemia using a univariate analysis (Table 2). These
analyses revealed that age, phenytoin coadministration, and GLUL
rs10797771 polymorphism showed p values <0.15 using the
200 mg/dL cutoff value, while age, gender, body weight, number of
antiepileptic drugs, phenytoin coadministration, acetazolamide
coadministration, nitrazepam coadministration, and GLUL
rs10797771 polymorphism showed p values < 0.15 using the
170 mg/dL cutoff value. We subjected these variables to a
multivariate logistic regression analysis performed using the
stepwise method (Table 3). This analysis revealed that phenytoin
coadministration (p < 0.001) and having the C allele in the GLUL
rs10797771 polymorphism (p = 0.044) were risk factors for
exceeding a plasma ammonia level of 200 mg/dL during VPA-
based therapy. The odds ratios of phenytoin coadministration and
having the C allele in the GLUL rs10797771 polymorphism were
5.919 [95% conﬁdence interval (95% CI), 2.220–15.780] and 2.817
(95% CI, 1.028–7.718), respectively. Age was not included in the
stepwise multivariate logistic regression analysis because it had a
p-value of >0.05 in the stepwise multivariate logistic regression
analysis.
In contrast, phenytoin coadministration (p < 0.001), having the
C allele in the GLUL rs10797771 polymorphism (p = 0.013), and
female gender (p = 0.037) were the risk factors for exceeding a
plasma ammonia level of 170 mg/dL during VPA-based therapy.
Nitrazepam coadministration had a p-value of <0.05 and was
included in the stepwise multivariate logistic regression analysis,
but was not signiﬁcantly different. The odds ratios of phenytoinTable 3
Multivariate logistic regression analysis for the determination of hyperammonemia
development during valproic acid-based therapy.
Variables1 (3200 mg/dL) OR (95% CI) p
Phenytoin coadministration 5.919 (2.220–15.780) <0.0013
Having C allele in GLUL rs10797771 2.817 (1.028–7.718) 0.0443
Variables2 (3170 mg/dL) OR (95% CI) p
Phenytoin coadministration 7.635 (3.077–18.944) <0.0013
Having C allele in GLUL rs10797771 3.151 (1.279–7.761) 0.0133
Female 2.653 (1.059–6.650) 0.0373
Nitrazepam coadministration 11.241 (0.789–160.048) 0.074
1 The 3 variables (age, phenytoin, and GLUL rs10797771 polymorphism) that
showed a moderate relationship (p < 0.15) with the development of hyperammo-
nemia (3200 mg/dL) in a univariate analysis were included in the stepwise
multivariate logistic regression analysis. Age was not included in the multivariate
logistic regression analysis. Odds ratio (OR) and 95% conﬁdence interval (95% CI)
show the relative risk of phenytoin coadministration compared with no additional
phenytoin administration or that of having the C allele (CC and CT genotypes)
compared with not having the C allele (TT genotype) in the GLUL rs10797771
polymorphism.
2 The 8 variables (age, gender, body weight, number of antipileptic drugs,
phenytoin, acetazolamide, nitrazepam, and GLUL rs10797771 polymorphism)
that showed a moderate relationship (p < 0.15) with the development of
hyperammmonemia (3170 mg/dL) in a univariate analysis were included in the
stepwise multivariate logistic regression analysis. Age, body weight, number of
anti-epileptic drugs, and acetazolamide coadministration were not included in
the stepwise multivariate logistic regression analysis. Nitrazepam coadminis-
tration was not signiﬁcantly different using the stepwise multivariate logistic
regression analysis. The OR and 95% CI show the relative risk of phenytoin
coadministration compared with no additional phenytoin administration, or
that of having the C allele (CC and CT genotypes) compared with not having the C
allele (TT genotype) in the GLUL rs10797771 polymorphism, or that of female
gender compared with male gender.
3 p < 0.05.coadministration, having the C allele in the GLUL rs10797771
polymorphism, and female gender were 7.635 (95%CI, 3.077–
18.944), 3.151 (95% CI, 1.279–7.761), and 2.653 (95% CI, 1.059–
6.650), respectively. Age, body weight, number of antiepileptic
drugs, and acetazolamide coadministration were not included in
the stepwise multivariate logistic regression analysis because
these 4 variables had p-values of >0.05 in the stepwise
multivariate logistic regression analysis.
4. Discussion
The incidence (9.9%) of exceeding 200 mg/dL as a plasma
ammonia level during VPA-based therapy in the present study was
higher than those (2.3 and 6.3%) in previous reports [6,7]. The
percentage of patients receiving VPA monotherapy in our study
may have been lower than that of the two previous reports because
concomitant antiepileptic drug use has been suggested as one of
the factors contributing to elevation of the plasma ammonia level
during VPA-based therapy [5]. In this study, we also provided the
incidence of exceeding a plasma ammonia level of 170 mg/dL
(100 mmol/L) during VPA-based therapy among pediatric patients
having epilepsy. There were only case reports about the association
between plasma ammonia levels expressed in mmol/L. There were
some reports stating that the hyperammonemia was deﬁned as
plasma ammonia level of 100 mmol/L (=170 mg/dL) outside VPA-
based therapy [15,16]. However, although this level has been
associated with neurological symptoms [17], there was no report
about the incidents of exceeding a plasma ammonia level of
170 mg/dL during VPA-based therapy. Tseng et al. reported that
6 of 44 patients showing plasma ammonia levels of more than
93 mg/dL during VPA-based therapy presented with nausea,
fatigue, ataxia, and consciousness disturbance [18]. In this study,
we did not examine clinical symptoms associated with hyper-
ammonemia development because they were not included in the
electronic medical records in detail. Further studies are necessary
to investigate the association between clinical symptoms and
elevated plasma ammonia levels.
We found that the GLUL rs10797771 polymorphism added to
phenytoin coadministration was a risk factor for the development
of severe hyperammonemia, with a plasma ammonia level
exceeding 200 mg/dL. In our previous studies, phenytoin coad-
ministration was the strongest risk factor for the development of
hyperammonemia [6,9]. The administration of phenytoin induces
the expression of drug metabolic enzymes, such as cytochrome
P450s and UDP-glucuronosyl transferases [19] which metabolize
VPA to 2-propyl-4-pentenoic acid, propionate, VPA-glucuronide,
and so on [20,21]. VPA metabolites, such as 2-propyl-4-pentenoic
acid and propionate, have been observed to potentiate the VPA-
associated accumulation of ammonia [22]. In this study, we did not
examine the association between the concentrations of these VPA
metabolites and plasma ammonia levels. Future studies are
warranted to investigate the correlation between the concentra-
tion of these VPA metabolites and plasma ammonia levels.
In this study, we found that the GLUL rs107997771 polymor-
phism is a novel risk factor for the development of severe
hyperammonemia during VPA-based therapy. As for GLUL
polymorphisms, patients having the C allele in the GLUL
rs10797771 polymorphism easily exceeded a plasma ammonia
level of 200 mg/dL during VPA-based therapy. GLUL rs10797771 is
located 165 bp upstream of the transcription start site (National
Center for Biotechnology Information reference sequence;
NG_013347). The association between the GLUL rs10797771
polymorphism and the enzymatic activity of glutamine synthetase
remains unclear. Furthermore, it was known that there are other
polymorphisms in GLUL gene. It has been reported that the
enzymatic activity of glutamine synthetase is decreased by
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expression of glutamine synthetase in glioblastoma patients
having epilepsy is lower than in those without epilepsy
[23]. Glutamine synthetase is expressed in the liver, brain,
gastrointestinal tract, and peripheral lymphocytes [10], while
the urea cycle functions only in the liver. If the plasma ammonia
level increases during liver failure, glutamine synthetase becomes
the key enzyme in ammonia clearance. In our opinion, it is
necessary to investigate the possible association between the
development of hyperammonemia and activity of glutamine
synthetase, including the effects of this or other GLUL polymor-
phisms and/or phenytoin coadministration.
Female gender was also found to be a risk factor for exceeding a
plasma ammonia level of 170 mg/dL during VPA-based therapy. In
this study, female patients had a signiﬁcantly higher mean VPA
daily dose than male patients (male vs. female, 20.65  8.13 mg/kg
vs. 24.62  10.16 mg/kg; p = 0.003) (data not shown). Previous
studies have reported a positive association between the VPA dose
and elevated plasma ammonia levels. Sharma et al. reported that
plasma ammonia levels (median, 79.2 mg/dL; range, 55.23–
114.29 mg/dL) are higher in the high-VPA-dose group (daily dose,
40–60 mg/kg) than the ammonia levels (median, 47.2 mg/dL; range,
20.62–73.25 mg/dL) in the low-dose group (daily dose, 20–39 mg/kg)
[2]. Furthermore, Itoh et al. reported that the daily VPA dose of
30.4 mg/kg is the cutoff value that predicts a plasma ammonia level
exceeding 60 mg/dL [24]. However, the median daily dose of VPA in
both males and females was lower than 30 mg/kg/day in this study.
Furthermore, we did not ﬁnd the association between the daily dose
of VPA and the development of hyperammonemia in the univariate
analysis (p < 0.15). Pleym et al. suggested that UDP-glucuronosyl
transferase activity is higher in males than in females, suggesting that
cytochrome P450-derived metabolites are more important in females
[25]. Cytochrome P450s converts VPA to its hepatotoxic metabolites,
such as 2-propyl-4-pentenoic acid [20,22]. Gender-based differences
of UDP-glucuronosyl transferase activity presumably account for the
differences in VPA metabolism and ammonia levels.
In conclusion, phenytoin coadministration, GLUL rs10797771
polymorphism in the 200 mg/dL cutoff value, and female in
addition to two factors in the 170 mg/dL cutoff value, are
independent risk factors for elevated plasma ammonia levels
during VPA-based therapy.
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